A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

NCT03924323•AbbVie

View on ClinicalTrials.gov

Summary

This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in it called a placebo. The purpose of this research is to study the safety and effectiveness of escitalopram in minors with GAD.

Eligibility

Age

7 - 17 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject's parent/legal representative must give written informed consent, including privacy authorization, prior to study participation. The subject will complete an informed assent prior to study participation.
•Subject meets DSM-5 criteria for a primary diagnosis of GAD at screening established by a comprehensive psychiatric evaluation and confirmed/supported using the Mini-International Neuropsychiatric Interview for children and adolescents (MINI Kid).
•Male subjects who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
•Female subjects who are sexually active and are of childbearing potential must use, with their partner, an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
•Female subjects who are not of childbearing potential do not need to use any methods of contraception. This includes preadolescent and adolescent females who have not reached menarche. - Subject must have venous access enough to allow blood sampling and be compliant with blood draws as per the protocol.

Exclusion Criteria

•Current diagnosis of MDD, attention-deficit/hyperactivity disorder, or lifetime diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, feeding and/or eating disorder, obsessive-compulsive disorder, conduct disorder, oppositional defiant disorder, post-traumatic stress disorder, panic disorder, or pervasive development disorder.
•Suspected or previously diagnosed intellectual disability disorder.
•One or more first-degree relatives with diagnosed bipolar I disorder.
•History of seizure disorder (other than febrile seizures).
•History of electroconvulsive therapy at any time during the subject's lifetime.
•Known hypersensitivity to escitalopram (escitalopram oxalate) or citalopram or any of the inactive ingredients or had frequent or severe allergic reactions to multiple medications.
•Taking any medications that are contraindicated to escitalopram (escitalopram oxalate).
•Inability to speak, read, or understand English well enough to complete the assessments.
•No active suicidal ideation or lifetime history of suicidal behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS).

Locations (39)

Harmonex /ID# 233342

Dothan, Alabama, United States

Woodland International Research Group /ID# 233348

Little Rock, Arkansas, United States

Woodland Research Northwest, LLC /ID# 233366

Rogers, Arkansas, United States

ATP Clinical Research, Inc /ID# 233362

Costa Mesa, California, United States

ProScience Research Group /ID# 233374

Culver City, California, United States

Sun Valley Research Center /ID# 233343

Imperial, California, United States

MCB Clinical Research Centers /ID# 233372

Colorado Springs, Colorado, United States

Emerson Clinical Research Inst /ID# 233371

Washington D.C., District of Columbia, United States

Innovative Clinical Research /ID# 233365

Fort Lauderdale, Florida, United States

Indago Research and Health Cen /ID# 233364

Hialeah, Florida, United States

Key Dates

Start Date

May 30, 2019

Primary Completion Date

September 20, 2021

Completion Date

September 20, 2021

Last Updated

November 14, 2022

Enrollment

273

ACTUAL participants

Conditions

Anxiety Disorders,Generalized Anxiety Disorder

Interventions

Escitalopram

DRUG

Placebo

OTHER